Exclusion Criteria:~* Labile blood pressure or new antihypertensive medication started within 3 weeks~* Severe
coronary insufficiency or myocardial infarction in previous 6 months~* History of unexplained syncope within
the preceding 12 months~* Cardiac Conduction Block~* Severe Hepatic Impairment (ALT > 120 (Upper Limit of
Normal (ULN) is 40) OR Alkaline Phosphatase > 390 (ULN 130)) OR Both ALT and total bilirubin > ULN OR Total
bilirubin > 60 (ULN 30)~* Severe Renal Impairment (eGFR < 40)~* Treatment with other medications known to
potentiate guanfacine's hypotensive effects or cause arrhythmia (specifically antipsychotics (including
sultopride, chlorpromazine, thioridazine, amisulpiride, sulpiride, haloperidol), and moxifloxacin, baclofen,
verapamil, quinidine, hydroquinidine, dispyramide, amiodarone, dofetilide, ibutilide, sotalol, pimazide,
bepridil, cisapride, diphemanil, erythromycin, halofantrine, pentamidine, sparfloxacin, vincamine, alfuzosin,
prazosin, terazosin, tamsulosin, amifostine~* Weight less than 45kg~* Pregnancy (Pre-menopausal women will only
be entered into the study of they are surgically sterile or using effective birth control methods: These are
abstinence for the period of the study, intrauterine contraception/device, male sexual partners with vasectomy)
